Mirjana Kovac1,2, Gorana Mitic3, Iva Djilas4, Milos Kuzmanovic5,6, Olivera Serbic6, Danijela Lekovic5,7, Branko Tomic8, Zsuzsanna Bereczky9. 1. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. mkovac008@gmail.com. 2. Blood Transfusion Institute of Serbia, Hemostasis Department, Sv. Save 39, Belgrade, 11000, Serbia. mkovac008@gmail.com. 3. Institute of Laboratory Medicine, Clinical Center of Vojvodina, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia. 4. Blood Transfusion Institute of Serbia, Hemostasis Department, Sv. Save 39, Belgrade, 11000, Serbia. 5. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 6. Institute for Health Care of Mother and Child of Serbia Dr Vukan Cupic, Belgrade, Serbia. 7. Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia. 8. Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia. 9. Division of Clinical Laboratory Research, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Abstract
Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the AT gene (SERPINC1). Considering that the genotype phenotype relationship in AT deficiency patients remains unclear, especially in pediatric patients, the aim of our study was to evaluate genotype phenotype correlation in a Serbian pediatric population. A retrospective cohort study included 19 children younger than 18 years, from 15 Serbian families, with newly diagnosed AT deficiency. In 21% of the recruited families, mutations affecting exon 4, 5, and 6 of the SERPINC1 gene that causes type I AT deficiency were detected. In the remaining families, the mutation in exon 2 causing type II HBS (AT Budapest 3) was found. Thrombosis events were observed in 1 (33%) of those with type I, 11 (85%) of those with AT Budapest 3 in the homozygous respectively, and 1(33%) in the heterozygous form. Recurrent thrombosis was observed only in AT Budapest 3 in the homozygous form, in 27% during initial treatment of the first thrombotic event. Abdominal venous thrombosis and arterial ischemic stroke, observed in almost half of the children from the group with AT Budapest 3 in the homozygous form, were unprovoked in all cases. Conclusion: Type II HBS (AT Budapest 3) in the homozygous form is a strong risk factor for arterial and venous thrombosis in pediatric patients. What is Known: • Inherited AT deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1gene. • The genotype phenotype correlation in AT deficiency patients remains unclear, especially in pediatric patients. What is New: • The genetic results for our paediatric population predominantly showed the presence of a single specific mutation in exon 2, that causes type II HBS deficiency (AT Budapest 3). • In this group thrombosis mostly occurred as unprovoked, in almost half of them as abdominal thrombosis or stroke with high incidence of recurrent thrombosis, in 27% during initial treatment.
Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the AT gene (SERPINC1). Considering that the genotype phenotype relationship in AT deficiencypatients remains unclear, especially in pediatric patients, the aim of our study was to evaluate genotype phenotype correlation in a Serbian pediatric population. A retrospective cohort study included 19 children younger than 18 years, from 15 Serbian families, with newly diagnosed AT deficiency. In 21% of the recruited families, mutations affecting exon 4, 5, and 6 of the SERPINC1 gene that causes type I AT deficiency were detected. In the remaining families, the mutation in exon 2 causing type II HBS (AT Budapest 3) was found. Thrombosis events were observed in 1 (33%) of those with type I, 11 (85%) of those with AT Budapest 3 in the homozygous respectively, and 1(33%) in the heterozygous form. Recurrent thrombosis was observed only in AT Budapest 3 in the homozygous form, in 27% during initial treatment of the first thrombotic event. Abdominal venous thrombosis and arterial ischemic stroke, observed in almost half of the children from the group with AT Budapest 3 in the homozygous form, were unprovoked in all cases. Conclusion:Type II HBS (AT Budapest 3) in the homozygous form is a strong risk factor for arterial and venous thrombosis in pediatric patients. What is Known: • Inherited AT deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1gene. • The genotype phenotype correlation in AT deficiencypatients remains unclear, especially in pediatric patients. What is New: • The genetic results for our paediatric population predominantly showed the presence of a single specific mutation in exon 2, that causes type II HBS deficiency (AT Budapest 3). • In this group thrombosis mostly occurred as unprovoked, in almost half of them as abdominal thrombosis or stroke with high incidence of recurrent thrombosis, in 27% during initial treatment.
Authors: Riten Kumar; Anthony K C Chan; Jennifer E Dawson; Julie D Forman-Kay; Walter H A Kahr; Suzan Williams Journal: Br J Haematol Date: 2014-03-29 Impact factor: 6.998
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: V Picard; A Bura; J Emmerich; M Alhenc-Gelas; C Biron; L L Houbouyan-Reveillard; P Molho; A Labatide-Alanore; P Sié; P Toulon; E Verdy; M Aiach Journal: Br J Haematol Date: 2000-09 Impact factor: 6.998
Authors: Gili Kenet; Lisa K Lütkhoff; Manuela Albisetti; Timothy Bernard; Mariana Bonduel; Leonardo Brandao; Stephane Chabrier; Anthony Chan; Gabrielle deVeber; Barbara Fiedler; Heather J Fullerton; Neil A Goldenberg; Eric Grabowski; Gudrun Günther; Christine Heller; Susanne Holzhauer; Alfonso Iorio; Janna Journeycake; Ralf Junker; Fenella J Kirkham; Karin Kurnik; John K Lynch; Christoph Male; Marilyn Manco-Johnson; Rolf Mesters; Paul Monagle; C Heleen van Ommen; Leslie Raffini; Kevin Rostásy; Paolo Simioni; Ronald D Sträter; Guy Young; Ulrike Nowak-Göttl Journal: Circulation Date: 2010-04-12 Impact factor: 29.690
Authors: V Limperger; A Franke; G Kenet; S Holzhauer; V Picard; R Junker; C Heller; C Gille; D Manner; K Kurnik; R Knoefler; R Mesters; S Halimeh; U Nowak-Göttl Journal: Thromb Haemost Date: 2014-06-26 Impact factor: 5.249
Authors: R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma Journal: Nature Date: 1994-05-05 Impact factor: 49.962
Authors: Guy Young; Manuela Albisetti; Mariana Bonduel; Leonardo Brandao; Anthony Chan; Frauke Friedrichs; Neil A Goldenberg; Eric Grabowski; Christine Heller; Janna Journeycake; Gili Kenet; Anne Krümpel; Karin Kurnik; Aaron Lubetsky; Christoph Male; Marilyn Manco-Johnson; Prasad Mathew; Paul Monagle; Heleen van Ommen; Paolo Simioni; Pavel Svirin; Daniela Tormene; Ulrike Nowak-Göttl Journal: Circulation Date: 2008-09-08 Impact factor: 29.690